BIOMARIN PHARMACEUTICAL ($BMRN) posted quarterly earnings results on Thursday, May 1st. The company reported earnings of $1.13 per share, beating estimates of $0.72 by $0.41. The company also reported revenue of $745,150,000, missing estimates of $755,534,706 by $-10,384,706.
You can see Quiver Quantitative's $BMRN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BIOMARIN PHARMACEUTICAL Insider Trading Activity
BIOMARIN PHARMACEUTICAL insiders have traded $BMRN stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $BMRN stock by insiders over the last 6 months:
- CHARLES GREG GUYER (EVP, Chief Technical Officer) has made 0 purchases and 2 sales selling 12,312 shares for an estimated $851,678.
- ERIN BURKHART (GVP, Chief Accounting Officer) has made 0 purchases and 2 sales selling 2,639 shares for an estimated $184,521.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BIOMARIN PHARMACEUTICAL Hedge Fund Activity
We have seen 284 institutional investors add shares of BIOMARIN PHARMACEUTICAL stock to their portfolio, and 279 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL RESEARCH GLOBAL INVESTORS added 2,496,817 shares (+23.8%) to their portfolio in Q4 2024, for an estimated $164,115,781
- JPMORGAN CHASE & CO removed 1,266,133 shares (-45.0%) from their portfolio in Q4 2024, for an estimated $83,222,922
- 1832 ASSET MANAGEMENT L.P. removed 1,164,391 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $76,535,420
- BANK OF NEW YORK MELLON CORP removed 1,021,389 shares (-42.6%) from their portfolio in Q1 2025, for an estimated $72,201,988
- SOLEUS CAPITAL MANAGEMENT, L.P. added 1,001,400 shares (+inf%) to their portfolio in Q4 2024, for an estimated $65,822,022
- BLACKROCK, INC. added 889,613 shares (+3.9%) to their portfolio in Q4 2024, for an estimated $58,474,262
- DODGE & COX added 847,917 shares (+6.1%) to their portfolio in Q4 2024, for an estimated $55,733,584
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BIOMARIN PHARMACEUTICAL Analyst Ratings
Wall Street analysts have issued reports on $BMRN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wedbush issued a "Outperform" rating on 11/04/2024
To track analyst ratings and price targets for BIOMARIN PHARMACEUTICAL, check out Quiver Quantitative's $BMRN forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
